Date: Thu, 18 Dec 1997 18:18:28 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1697
Last-modified: Mon, 06 Oct 1997 21:49:12 GMT

<html>
<head>
<title>Neoprobe Corporation 1995 Annual Report - WWW Version - Page 1</title>
</head>
<body bgcolor="ffffff">
<center><img width=422 height=61 src="../../images/providing.gif"></center>
<BLOCKQUOTE>
<font size=+1><em>In 1995, solid-tumor cancers struck an estimated 1.1 million people in the United States and claimed almost half a million lives. Surgery <img width=183 height=325 src="../../images/handprobe.jpg" ALIGN=left>is still considered the foremost and best treatment for most of these people. Neoprobe Corporation has taken on the challenge of enhancing the care of these patients by developing the company’s RIGS technology for improving cancer surgery.
<p>In the past year, Neoprobe finished clinical testing for our first product, RIGScan<sup><font size=-2>&reg;</font></sup> CR49, for detection and treatment of metastatic colorectal cancer during surgery. 
<p>Today, we are preparing applications for marketing and commercializing RIGScan CR49. This is the story of the company’s progress in meeting the challenge of cancer care.</em></font>
</BLOCKQUOTE>
<center>
<table>
	<tr>
	<td><a href="letter_1995.html"><img width=50 height=27 src="../../images/left-arrow.gif" border=0></a></td><td><a href="index.html"><img width=81 height=20 src="../../images/index-button.gif" border=0></a><br><a href="../../index.html"><img width=81 height=21 src="../../images/home-button.gif" border=0></a></td><td><a href="Page2.html"><img width=50 height=27  src="../../images/right-arrow.gif" border=0></a></td>
	</tr>
</table>
</center>
</body>
<img width=1 height=1 src="../../images/vialing.jpg">
<img width=1 height=1 src="../../images/creating.gif">
</html>